A drug to treat hemophilia, Non-Hodgkin lymphoma & more: 4 latest FDA approvals

Here are four drugs or medical devices that have been approved by the FDA since Aug. 24:

1. Jivi, manufactured by Bayer, is a long-acting treatment for hemophilia A, a rare, genetic bleeding disorder. It is an injection for patients 12 years or older.

2. Imbruvica plus Rituxan, is a combination drug for the treatment of adult patients with Waldenstrom macroglobulinemia, a rare and incurable type of Non-Hodgkin lymphoma.

3. Merck received FDA approval for Delstrigo, a once-daily fixed-dose combination tablet of doravirine, lamivudine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.

4. Pifeltro is a non-nucleoside reverse transcriptase inhibitor, which is to be used in combination with other antiretroviral medicines for the treatment of HIV-1 infection in adults.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars